Nuzenio

Positive Nsclc

Positive Nsclc news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Long-term outcomes with lorlatinib vs. crizotinib in ALK-positive NSCLC: Insights from the CROWN study: Written recap - managedhealthcareexecutive.commanagedhealthcareexecutive.com · Wed, 05 Aug 2026 23:52:19 GMTFDA Approval of Zidesamtinib for ROS1-Positive NSCLC – IASLC - OncodailyOncodaily · Tue, 04 Aug 2026 16:44:58 GMTASCO Living Guideline Update Expands Targeted Options in Advanced NSCLC - Targeted OncologyTargeted Oncology · Mon, 03 Aug 2026 13:06:17 GMTFDA approves GSK's Jideytro for previously treated ROS1-positive NSCLC, the company's first lung cancer clearance - OncodailyOncodaily · Wed, 29 Jul 2026 11:32:06 GMTELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC - The ASCO PostThe ASCO Post · Tue, 28 Jul 2026 14:29:40 GMTAdjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC - CancerNetworkCancerNetwork · Mon, 27 Jul 2026 14:38:02 GMTJideytro Approved for Previously Treated ROS1-Positive NSCLC - Clinical Oncology NewsClinical Oncology News · Mon, 27 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 23:52:19 GMTLong-term outcomes with lorlatinib vs. crizotinib in ALK-positive NSCLC: Insights from the CROWN study: Written recap - managedhealthcareexecutive.com
Tue, 04 Aug 2026 16:44:58 GMTFDA Approval of Zidesamtinib for ROS1-Positive NSCLC – IASLC - Oncodaily
Mon, 03 Aug 2026 13:06:17 GMTASCO Living Guideline Update Expands Targeted Options in Advanced NSCLC - Targeted Oncology
Wed, 29 Jul 2026 11:32:06 GMTFDA approves GSK's Jideytro for previously treated ROS1-positive NSCLC, the company's first lung cancer clearance - Oncodaily
Tue, 28 Jul 2026 14:29:40 GMTELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC - The ASCO Post
Mon, 27 Jul 2026 14:38:02 GMTAdjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC - CancerNetwork

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Positive Nsclc.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.